Big Pharma's Top 5 Emerging Market Deals

With pharmaceutical sales in major markets like the United States, Europe and Japan slowing, a number of big drugmakers have looked outside of traditional territories to emerging markets. Eastern Europe, Russia, South America, the Middle East and Asia have all become sought-after markets as Big Pharma begins its emerging markets land-grab.

We've ranked the top five emerging market deals in the last 12 months. GlaxoSmithKline, which has been particularly aggressive about making deals in foreign markets, has three of our top five deals. But Abbott's $3.7 billion deal for India's Priamal takes the top spot. Click here to see the details. Report >>

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.